- Home
- RLAY vs REPL Comparison
RLAY vs REPL Comparison
Compare RLAY & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- REPL
- Stock Information
- Founded
- RLAY 2015
- REPL 2015
- Country
- RLAY United States
- REPL United States
- Employees
- RLAY N/A
- REPL N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- RLAY Health Care
- REPL Health Care
- Exchange
- RLAY Nasdaq
- REPL Nasdaq
- Market Cap
- RLAY 610.3M
- REPL 547.0M
- IPO Year
- RLAY 2020
- REPL 2018
- Fundamental
- Price
- RLAY $3.54
- REPL $5.56
- Analyst Decision
- RLAY Strong Buy
- REPL Buy
- Analyst Count
- RLAY 12
- REPL 10
- Target Price
- RLAY $18.45
- REPL $8.25
- AVG Volume (30 Days)
- RLAY 2.8M
- REPL 24.2M
- Earning Date
- RLAY 08-07-2025
- REPL 08-07-2025
- Dividend Yield
- RLAY N/A
- REPL N/A
- EPS Growth
- RLAY N/A
- REPL N/A
- EPS
- RLAY N/A
- REPL N/A
- Revenue
- RLAY $8,355,000.00
- REPL N/A
- Revenue This Year
- RLAY $17.59
- REPL N/A
- Revenue Next Year
- RLAY N/A
- REPL $194.05
- P/E Ratio
- RLAY N/A
- REPL N/A
- Revenue Growth
- RLAY N/A
- REPL N/A
- 52 Week Low
- RLAY $1.78
- REPL $2.68
- 52 Week High
- RLAY $10.72
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- RLAY 52.25
- REPL 44.05
- Support Level
- RLAY $3.31
- REPL $4.49
- Resistance Level
- RLAY $3.61
- REPL $6.39
- Average True Range (ATR)
- RLAY 0.21
- REPL 0.77
- MACD
- RLAY -0.02
- REPL 0.09
- Stochastic Oscillator
- RLAY 68.67
- REPL 48.77
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.